Which medication is not recommended for initial treatment of allergic rhinitis in this age group?

For the initial treatment of allergic rhinitis, long-acting beta-agonists (LABAs) are not recommended. These medications are primarily used for the management of asthma and chronic obstructive pulmonary disease (COPD), as they act on beta-2 adrenergic receptors to relax bronchial smooth muscle and improve airflow. They do not address the underlying inflammatory processes associated with allergic rhinitis.

In contrast, options such as intranasal corticosteroids, oral antihistamines, and montelukast are more appropriate for managing allergic rhinitis. Intranasal corticosteroids are the first-line treatment due to their effectiveness at reducing nasal inflammation, while oral antihistamines are widely used to alleviate symptoms such as sneezing and itching. Montelukast, a leukotriene receptor antagonist, can also be beneficial, although it is typically considered when other therapies are not effective.

Using LABAs for allergic rhinitis does not align with current guidelines, as they do not target the specific symptoms or pathophysiology related to this condition. Therefore, selecting a medication that specifically addresses allergic rhinitis symptoms is crucial for effective management.